Navigation Links
Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Date:8/26/2009

DURHAM, N.C., Aug. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

Kirk Harrington, senior vice president, Warfighter Division and Government Affairs, will present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 9, 2009 at 2:00 p.m. eastern time.

A live, audio webcast of Harrington's presentation will be available through the Investor Relations section of the Oxygen Biotherapeutics, Inc. website. A replay will be available following the event. Webcast login information will be provided on the company website prior to the presentation.

The following day, the company chairman and CEO, Chris Stern, will present at an investor conference in Zurich. The presentation will be at the Dolder Grand Hotel and is scheduled for 5:00 p.m. in the Garden Salon. The Zurich presentation will not be webcast but will be open to interested investors.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
10. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
11. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Vermillion, Inc. (NASDAQ: VRML ), ... announced the formation of the Steering Committee for its ... --> Pelvic masses can present physicians and ... Once pregnancy is ruled out, pelvic masses may include ... endometriosis, benign ovarian tumors and gastrointestinal and urinary tract ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant announces ... "Stem Cell Research Products, Opportunities, Tools, and Technologies – ... The ... the stem cell industry, BioInformant has more than a ... stem cell market, by stem cell type. This powerful ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
Breaking Biology Technology:
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):